Physician profile
Nadia Yaqub
NPI 1891750287
$4,873.15
in general payments reported to CMS, 2019-2025
39 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $222 · 2021: $571 · 2022: $788 · 2023: $670 · 2024: $575 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.81 |
| Education | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $622.99 | 2019-2024 | Ozempic, Rybelsus |
| Insulet Corporation | $314.64 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $308.60 | 2019-2025 | Mounjaro, Jardiance, Humulin |
| Medtronic, INC. | $279.25 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.61 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $240.89 | 2019-2024 | |
| Amarin Pharma, INC. | $230.75 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $221.86 | 2022-2025 | Ingrezza, Ongentys |
| Amgen INC. | $204.06 | 2019-2023 | Prolia, Evenity, Repatha |
| Abbott Laboratories | $202.73 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $191.18 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $166.52 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $160.84 | 2022-2025 | Afrezza |
| Medtronic Minimed, INC. | $149.70 | 2019 | |
| Horizon Therapeutics Plc | $144.29 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $141.07 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $105.25 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $96.93 | 2019-2023 | Steglatro, Steglujan |
| Genzyme Corporation | $92.92 | 2020-2022 | |
| Beta Bionics, INC. | $90.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $85.68 | 2023-2025 | Dexcom G6 Transmitter |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $63.25 | 2022 | |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Antares Pharma, INC. | $48.38 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Sequel Med Tech, LLC | $46.29 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $40.23 | 2024 | |
| Abbvie INC. | $29.59 | 2020-2022 | |
| Shire North American Group INC | $26.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.87 | 2020 | |
| Amneal Pharmaceuticals LLC | $25.02 | 2022 | |
| Cequr Corporation | $21.36 | 2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $19.90 | 2023 | Tirosint, Licart |
| Halozyme INC | $19.80 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.90 | 2023 | Adthyza |
| Acella Pharmaceuticals, LLC | $16.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.07 | 2021 | |
| Vivus LLC | $7.69 | 2019 | |
| Lifescan, INC. | $7.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Yaqub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.